8-K: Aprea's APR-1051 Shows Early Activity in Cancer Trial

Aprea Therapeutics announced early signals of activity for its WEE1 Kinase Inhibitor APR-1051 in the ACESOT-1051 trial, with 3 out of 4 patients achieving stable disease at the 100 mg dose level.

Summary

• Preliminary results from the Phase 1 ACESOT-1051 trial for WEE1 Kinase Inhibitor APR-1051 show early signals of anti-tumor activity.
• At the 100 mg APR-1051 dose level, 3 out of 4 patients (75%) achieved stable disease, as measured by RECIST v1.1 criteria.
• Patients in the trial had heavily pretreated gastrointestinal and gynecologic malignancies.
• Disease stabilization was observed in patients with tumors harboring mutations relevant to WEE1 kinase inhibition, specifically FBXW7, CCNE1, KRAS G12V, and TP53 alterations.
• The trial reported favorable tolerability with no dose-limiting toxicities (DLTs) or unexpected safety issues to date.
• Following successful clearance of the 100 mg cohort, dose escalation has progressed to Dose Level 7 (150 mg).
• Preliminary results through September 17, 2025, will be presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.

Sentiment

Score: 8

Explanation: The preliminary Phase 1 results for APR-1051 show promising early signals of efficacy (75% stable disease) and good tolerability in a challenging, heavily pretreated patient population. This supports continued dose escalation and development, indicating a positive outlook for the drug candidate.

Positives

• Early signals of anti-tumor activity for APR-1051 were observed in a heavily pre-treated patient population.
• 75% (3 out of 4) of patients achieved stable disease at the 100 mg dose level, indicating potential efficacy.
• Disease control was observed in tumors with specific mutations (FBXW7, CCNE1, KRAS G12V, TP53) that align with the mechanistic understanding of WEE1 inhibition.
• Favorable tolerability was reported, with no dose-limiting toxicities or unexpected safety issues.
• The successful clearance of the 100 mg cohort allowed for progression to the next dose level (150 mg), indicating safety at the current dose.

Negatives

• One patient (25%) treated at the 100 mg dose level experienced disease progression at the first assessment.
• One patient voluntarily withdrew consent after approximately two months of treatment, despite achieving stable disease at the first evaluation.
• The results are preliminary, based on a small patient cohort in a Phase 1 dose escalation study.

Risks

• The success, timing, and cost of ongoing and anticipated clinical trials for product candidates are uncertain.
• There is a risk regarding the ability to fully fund disclosed clinical trials, assuming no material changes to currently projected expenses.
• Futility analyses, presentations at conferences, and data reported in abstracts are not necessarily indicative of the final results of ongoing clinical trials.
• The ability to predict clinical outcomes based on preclinical and early clinical results is uncertain.
• There are risks related to the company's ability to continue as a going concern.
• Other risks, uncertainties, and factors described in the company's SEC filings under 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operations' could materially affect actual results.

Future Outlook

Dose escalation continues in the ACESOT-1051 study, with patients now enrolling in the 150 mg cohort. The company anticipates providing further updates as the study advances to higher dose levels.

Management Comments

• Dr. Philippe Pultar stated, "We continue to be encouraged by these early clinical findings, which demonstrate signals of anti-tumor activity with APR-1051 in a heavily pre-treated patient population."
• Dr. Pultar also noted, "We believe the observation of disease control in tumors harboring FBXW7, CCNE1, and KRAS mutations align with our mechanistic understanding of WEE1 inhibition and reinforces the scientific rationale for APR-1051 development."
• Dr. Pultar added, "We believe these promising data provide an important foundation as we continue with dose escalation in the ongoing study and we look forward to providing further updates as we advance to higher dose level in the ongoing study."

Industry Context

Aprea Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel cancer therapies that exploit specific cancer cell vulnerabilities while minimizing harm to healthy cells. APR-1051, a WEE1 kinase inhibitor, and ATRN-119, an ATR inhibitor, are part of a growing class of targeted oncology treatments that interfere with DNA damage response pathways. This approach aims to selectively eradicate tumors by targeting specific mutations, potentially offering a more precise and less toxic alternative to conventional chemotherapy, aligning with broader industry trends towards personalized and targeted cancer medicine.

Comparison to Industry Standards

• The filing does not provide specific comparisons to other companies, projects, or industry benchmarks for WEE1 kinase inhibitors or similar targeted therapies.

Stakeholder Impact

• Shareholders: Positive early clinical data could enhance investor confidence and potentially influence the company's stock performance.
• Patients: The early signals of activity offer potential new treatment options for individuals with heavily pretreated gastrointestinal and gynecologic malignancies.
• Employees: Favorable trial results can boost morale and validate the company's research and development efforts.

Next Steps

• Continue dose escalation in the ACESOT-1051 study, with patients currently enrolling in the 150 mg cohort.
• Present preliminary results from the ACESOT-1051 trial at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
• Provide further updates on the ACESOT-1051 study as it advances to higher dose levels.

Key Dates

Recommendation

The early Phase 1 clinical data for APR-1051 demonstrates promising signals of anti-tumor activity, with 75% of heavily pretreated patients achieving stable disease, and favorable tolerability. The observed disease control in tumors with relevant mutations reinforces the scientific rationale. While preliminary, these results provide a strong foundation for continued development and suggest significant upside potential if later-stage trials confirm efficacy, making it an attractive "buy" for investors with a higher risk tolerance in the biotech sector.

Keywords

Aprea Therapeutics, APR-1051, WEE1 Kinase Inhibitor, ACESOT-1051, Phase 1 trial, Oncology, Cancer treatment, Solid tumors, Clinical update, Biopharmaceutical, Stable disease, RECIST v1.1, FBXW7, CCNE1, KRAS G12V, TP53, Gastrointestinal cancer, Gynecologic cancer